Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK

Open source

DOI: 10.1136/esmoopen-2020-000714
Published: 2020 Aug
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/esmoopen-2020-000714,
  title = {Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.},
  author = {Kelley RK and Ryoo BY and Merle P and Park JW and Bolondi L and Chan SL and Lim HY and Baron AD and Parnis F and Knox J and Cattan S and Yau T and Lougheed JC and Milwee S and El-Khoueiry AB and Cheng AL and Meyer T and Abou-Alfa GK},
  year = {2020},
  journal = {ESMO open},
  doi = {10.1136/esmoopen-2020-000714},
  url = {https://doi.org/10.1136/esmoopen-2020-000714}
}

RIS

TY  - JOUR
TI  - Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
AU  - Kelley RK
AU  - Ryoo BY
AU  - Merle P
AU  - Park JW
AU  - Bolondi L
AU  - Chan SL
AU  - Lim HY
AU  - Baron AD
AU  - Parnis F
AU  - Knox J
AU  - Cattan S
AU  - Yau T
AU  - Lougheed JC
AU  - Milwee S
AU  - El-Khoueiry AB
AU  - Cheng AL
AU  - Meyer T
AU  - Abou-Alfa GK
PY  - 2020
JO  - ESMO open
DO  - 10.1136/esmoopen-2020-000714
UR  - https://doi.org/10.1136/esmoopen-2020-000714
ER  -

APA

RK, K., BY, R., P, M., JW, P., L, B., SL, C., HY, L., AD, B., F, P., J, K., S, C., T, Y., JC, L., S, M., AB, E., AL, C., T, M., & GK, A. (2020). Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.. ESMO open. https://doi.org/10.1136/esmoopen-2020-000714

Source records

pubmed · retrieved 2026-09-25T19:09:15.815Z
europe-pmc · retrieved 2026-09-25T19:09:15.821Z
hal · retrieved 2026-09-25T19:09:15.890Z